Somatropin biosimilar - Biopartners/LG Life Sciences

Drug Profile

Somatropin biosimilar - Biopartners/LG Life Sciences

Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin BioPartners; SR-rhGH; Valtropin

Latest Information Update: 04 Jun 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Developer Biopartners GmbH; LG Life Sciences; Merck KGaA
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Phase III Prader-Willi syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Jun 2015 Somatropin biosimilar controlled release is still in phase III development for Somatotropin deficiency in adults and paediatric patients worldwide (including USA)
  • 01 Jun 2014 Phase-III clinical trials in Prader-Willi syndrome (In children) in South Korea (SC) (NCT02204163)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top